Additional inhibitors were combined with two activators of iBK formation: the highly selective Kunitz-type plasmin inhibitor, DX-1000 [2] and lanadelumab, a plasma kallikrein inhibitor recently introduced in clinical use for the prevention of HAE attacks [4, 15]. The gene discussed is KLK4; the disease is hereditary angioedema.